Prognostic value of S-100 immunostaining in tumour cells of non-small cell lung cancer

Author： Jassem E.   Serkies K.   Dziadziuszko R.   Drozdowska A.   Kobierska-Gulida G.   Skokowski J.   Góźdź S.   Urbaniak A.   Sygut J.   Jassem J.  

Publisher： Informa Healthcare

ISSN： 1366-5804

Source： Biomarkers, Vol.11, Iss.3, 2006-05, pp. : 262-269

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

The development of immunotherapies for non-small cell lung cancer

By Salgaller Michael L  

Expert Opinion on Biological Therapy, Vol. 2, Iss. 3, 2002-03 ,pp. : 265-278

Informa Healthcare

Access to resources Recommend Favorite

Cetuximab in non-small cell lung cancer

By Ademuyiwa Foluso O   Hanna Nasser  

Expert Opinion on Biological Therapy, Vol. 8, Iss. 1, 2008-01 ,pp. : 107-113

Informa Healthcare

Access to resources Recommend Favorite

Serum interleukin-17 as a diagnostic and prognostic marker for non-small cell lung cancer

By Xu Chunhua   Hao Keke   Yu Like   Zhang Xiuwei  

Biomarkers, Vol. 19, Iss. 4, 2014-06 ,pp. : 287-290

Informa Healthcare

Access to resources Recommend Favorite

miR-96 downregulates RECK to promote growth and motility of non-small cell lung cancer cells

By Guo Haizhou   Li Qianping   Li Weihao   Zheng Tianliang   Zhao Song   Liu Zhangsuo  

Molecular and Cellular Biochemistry, Vol. 390, Iss. 1-2, 2014-05 ,pp. : 155-160

Springer Publishing Company

Access to resources Recommend Favorite

miR‐134 inhibits epithelial to mesenchymal transition by targeting FOXM1 in non‐small cell lung cancer cells

By  

FEBS Open Bio, Vol. 586, Iss. 20, 2012-10 ,pp. : 3761-3765

John Wiley & Sons Inc

Access to resources Recommend Favorite